
WisdomTree Europe Quality Dividend Growth Fund (EUDG) Price & Chart
EUDG ETF Chart & Stats
- Day’s Range
- $38.27 - $38.65
- 52-Week Range
- $34.77 - $40.59
- Previous Close
- $38.62
- Volume
- 1,265
- Average Volume (3M)
- 3,564
- AUM
- 67.77M
- NAV
- 38.52
- Expense Ratio
- 0.58%
- Holdings Count
- 230
- Beta
- 0.63
- Inception Date
- May 07, 2014
- Last Dividend Ex-Date
- Sep 25, 2026
- Dividend Yield
- (2.36%)
- Shares Outstanding
- 1,750,000
- Standard Deviation
- N/A
ETF Overview
WisdomTree Europe Quality Dividend Growth Fund
The WisdomTree Europe Quality Dividend Growth Fund, trading under the ticker EUDG, is a compelling investment vehicle designed to capture the essence of Europe's total market through a focused lens on size and style. This ETF meticulously targets the broad-based niche of dividend growth, providing investors with exposure to a curated selection of high-quality European companies known for their robust dividend-paying capabilities. EUDG stands out by prioritizing firms that not only offer reliable dividends but also exhibit strong growth potential and superior financial health. This focus on quality dividend growth ensures that investors are not merely gaining access to companies with high yields, but to those with a sustainable and scalable dividend policy backed by solid earnings growth. The ETF's comprehensive approach encompasses a diverse range of industries across the European market, presenting a balanced exposure that mitigates risks while capitalizing on the region's economic vitality. For investors seeking to enhance their portfolios with a blend of stability and growth potential, the WisdomTree Europe Quality Dividend Growth Fund represents a strategic and sophisticated option in the landscape of global investing.
- Asset Class
- Equity
- Region
- Europe
- Issuer
- WisdomTree
- Index Tracked
- WisdomTree Europe Quality Dividend Growth Index
- Ticker Symbol
- EUDG
EUDG ETF News


AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s official study title is Breast Cancer Real-World Insights and Decision Guidance Evaluation (BRIDGE-HK) An Observational, Retrospective,

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s NCT07685600 study, officially titled “An Open-label, Randomised, Two Arm, Fixed Sequence Study in Healthy Participants to
EUDG ETF FAQ
What was EUDG’s price range in the past 12 months?
What is the AUM of EUDG?
Is EUDG overvalued?
Does EUDG pay dividends?
How many shares outstanding does EUDG have?
Top 10 Holdings
| Name | Weight % |
|---|---|
| NESNNestlé | 5.43% |
| NOVNNovartis | 5.16% |
| ROPRoche Holding | 4.57% |
| MCLVMH Moet Hennessy Louis Vuitton (UK) | 4.09% |
| NOVO.BDK:NOVO.B | 3.51% |
| ITXINDUSTRIA DE DISENO TEXTIL | 3.39% |
| AZNAstraZeneca plc | 3.15% |
| BBVABanco Bilbao Vizcaya Argentaria SA | 2.85% |
| UCGUniCredit S.p.A | 2.72% |
| ORL'Oreal S.A. (UK) | 2.68% |
| Total | 37.56% |











